Literature DB >> 6174257

Diagnosis of Refsum's disease using [1-14C]phytanic acid as substrate.

A Poulos.   

Abstract

The suitability of using [1-14C]phytanic acid as a substrate for the diagnosis of Refsum's disease has been examined. Normal fibroblasts cultured in medium containing low concentrations of foetal calf serum (0.5%) oxidised added [1-14C]phytanic acid to 14CO2 only slowly up to about 2 days; beyond this period a marked stimulation in oxidation was observed. Easily measurable conversion of the radiolabelled acid (from 1.5 to 5.0%) was obtained by numbers of cells at least one order of magnitude fewer than previously described. Fibroblasts from adult patients with Refsum's disease displayed about 5-10% of the normal mean activity. Small differences in residual activity were observed in the different cell lines. However, no obvious relationship was found between the degree of residual activity, the level of plasma phytanate, and the patient's clinical condition and history.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6174257     DOI: 10.1111/j.1399-0004.1981.tb01029.x

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  17 in total

1.  Accumulation of phytanic acid alpha-oxidation intermediates in Zellweger fibroblasts.

Authors:  R Fingerhut; W Schmitz; E Conzelmann
Journal:  J Inherit Metab Dis       Date:  1993       Impact factor: 4.982

2.  Infantile Refsum's disease: biochemical findings suggesting multiple peroxisomal dysfunction.

Authors:  B T Poll-The; J M Saudubray; H Ogier; R B Schutgens; R J Wanders; G Schrakamp; H van den Bosch; J M Trijbels; A Poulos; H W Moser
Journal:  J Inherit Metab Dis       Date:  1986       Impact factor: 4.982

3.  The significance of plasma phytanic acid levels in adults.

Authors:  T C Britton; F B Gibberd; M E Clemens; J D Billimoria; M C Sidey
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-07       Impact factor: 10.154

4.  Metabolism of saturated and polyunsaturated very-long-chain fatty acids in fibroblasts from patients with defects in peroxisomal beta-oxidation.

Authors:  J M Street; H Singh; A Poulos
Journal:  Biochem J       Date:  1990-08-01       Impact factor: 3.857

5.  Phytanic acid alpha-oxidation and complementation analysis of classical Refsum and peroxisomal disorders.

Authors:  B T Poll-The; O H Skjeldal; O Stokke; A Poulos; F Demaugre; J M Saudubray
Journal:  Hum Genet       Date:  1989-01       Impact factor: 4.132

6.  Cerebro-hepato-renal (Zellweger) syndrome, adrenoleukodystrophy, and Refsum's disease: plasma changes and skin fibroblast phytanic acid oxidase.

Authors:  A Poulos; P Sharp; A J Fellenberg; D M Danks
Journal:  Hum Genet       Date:  1985       Impact factor: 4.132

7.  Metabolism of saturated and polyunsaturated fatty acids by normal and Zellweger syndrome skin fibroblasts.

Authors:  J M Street; D W Johnson; H Singh; A Poulos
Journal:  Biochem J       Date:  1989-06-15       Impact factor: 3.857

8.  The deficient degradation of synthetic 2- and 3-methyl-branched fatty acids in fibroblasts from patients with peroxisomal disorders.

Authors:  P P Van Veldhoven; S Huang; H J Eyssen; G P Mannaerts
Journal:  J Inherit Metab Dis       Date:  1993       Impact factor: 4.982

9.  Prenatal diagnosis of Zellweger syndrome and related disorders: impaired degradation of phytanic acid.

Authors:  A Poulos; C van Crugten; P Sharp; W F Carey; E Robertson; D M Becroft; J M Saudubray; B T Poll-The; E Christensen; N Brandt
Journal:  Eur J Pediatr       Date:  1986-12       Impact factor: 3.183

10.  Ultrastructure and immunocytochemistry of hepatic peroxisomes in rhizomelic chondrodysplasia punctata.

Authors:  J L Hughes; A Poulos; D I Crane; C W Chow; L J Sheffield; D Sillence
Journal:  Eur J Pediatr       Date:  1992-11       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.